Omnicare, Inc., continues to defend a consolidated shareholder derivative lawsuit pending in Kentucky, according to the Company’s October 25, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended September 30, 2011.
On February 13, 2006,…
Merck & Co., Inc., disclosed in its August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30, 2011, that expert discovery in the NuvaRing litigation is expected to be completed by…
In July 2011, the United States District Court for the District of Massachusetts dismissed the majority of Plaintiff’s claims in the lawsuit captioned United States of America ex rel Tricia Nowak and Enda Dodd v. Medtronic, Inc., according to the…
Merck & Co., Inc., is awaiting a court decision on its motion to dismiss a derivation action captioned Rose v. Hassan, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the…
Trial of Qui Tam actions involving Amgen Inc. in Massachusetts will start on October 3, 2011, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30, 2011.
A…
Merck & Co., Inc., continues to defend lawsuits relating to average wholesale prices pending in various states, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30,…
Amgen Inc. is awaiting a court decision on its and other defendants’ motion to dismiss the lawsuit State of Louisiana v. Abbott Laboratories, Inc., et al., according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities…
An appeal from the dismissal of a stockholder derivative lawsuit captioned Birch v. Sharer, et al., remains pending, Amgen Inc. disclosed in its August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended…
Forest Laboratories Inc. disclosed in its latest annual report on Form 10-K filed with the U.S. Securities and Exchange Commission that in March 2011, the company entered into a Stipulation of Settlement to resolve two derivative actions brought against its…
Forest Laboratories Inc. disclosed in its latest annual report on Form 10-K filed with the U.S. Securities and Exchange Commission that the company received a subpoena dated April 20, 2011 from the Office of the U.S. Attorney for the District…